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INTRODUCTION
There  has  no t  been a  lo t  o f  change in  the
pharmaceutical indr-rstry in Indonesia for the last 30
years. In the global market. the pharrnaceutical market
in lndonesiaonly reached Rp l5 tril l ions in 2002 which
is below I % ofthe world's phamaceutical rnarket. In
the year 2003 -200 4, I ndonesia's pharmaceutical market
was predicted to have a 20oh growth dLre to the
immense need ofmedicine. The medicines in Indonesia
are stil l imporled thus make the price go high while tlie
purchasing power is still low therefore the investors need
to invest a lot in the pharrnaceutical industry sector so
that the price can be pushed to be affordable for the
domestic market. Another plrenomenorr due to the low
purchasing power is tlre irrcrease demand for over the
counter rnedicine.
The prescribed rugs that can only be purchased
with a doctor's receipt are expensive, on the other
hand over the counter drugs are rnore affordable.
Therefore during the cr is is,  as purchasing power
decrease significantly, people tend to buy more over
the counter drLrgs to treat their il lnesses. This self-
rnedication phenomenort has caused the dernand for
over the counter drug increase significantly in the
domestic market.
V o l .  7 .  N o .  I
Tlre increase in consur.ners' awareness for a better
hea l th  has  opened a  huge oppor tun i ty  fo r  the
pharmaceutical industry to develop fast. This was proven
by the huge demand for energ'drink and multivitamins.
Tlrerefore many pharmaceutical companies race with
one another in fulfil l ing consunler's demand for those
kind of over the counter drugs such as influenza,
headaches, rnultivitarnirrs and energy drinks. Sorne
companies uch as Dankos Laboratories Tbk successfully
had significant increase of 37.lohorRp782.2 bill ions in
earnings in the third quarter of 2002 due to tlre sale of
their over the counter drugs. Others also had significant
increase of earnings such as PT Bintang Toedjoe with
its Extra Joss@, lrex@, Joss Kids@, Waisan@, Komik@
products. The subsidiary company of PT Dankos
Laboratory, Kalbe Farma, also actively prodLrces OTC
(Over The Counter) drugs. The contribution of income
from prescribed rLrgs decreased from23.4Yo in 2001
to 18.6Y0 in 2002 therefore most of the increase
earnings was due to the increase sale ofOTC in drugs
and also due to tlie strengthening of RLrpiah against
US Dollar. Other pharmaceutical companies uch as
PT Kirnia Farma, and PT Indofarma Tbk also actively
and progressively tried to sell OTC drugs thoLrgh not
as active and progressive as PT Dankos Laboratory
Tbk.
Analysis of Financial performance affecting
Stock Price on Pharmaceutical Industrv
RUSKY AVIANDY
Lembaga Penelit ian Semeru
Jl. TulungAgung 460 Menteng, Central Jakarta
Ph: 021.8009240, Hp: 081 I I 06865
Accepted on 6th August 2007, Approved 8th September 2007
Abstract :  This  research is  conducted to analyze the in f luence of  s tock pr ice of  f i rms in the
pharmaceutical industry as l isted in the JSX using financial ratios and based on the Gordon model
approach. Methodology used in this research was Gordon model to know the stock's intrinsic value from
each firm, then the comparison of market stock price, and analysis using regression analysis to know
which factors affect stock price and how big the influence is. This research used six research variables;
ROA, ROE, payout ratio, book value per share. and debt to equity ratio. The research population was
pharrnacer.rt ical onrpanies l isted on the JSX until the end of 2004. It can be concluded that ROA, ROE,
book value per share, and debt to equity has a very weak influence to stock price. Only payout ratio has
the significant influence to stock price of f inns in the pharmaceutical industry l isted on the JSX. There is
significant effect f i 'om return on asset, return on equity, payout ratio, book value per share and debt to
equity ratio altogether to market price of f irms in pharrnaceutical industry.
Keywords: Gordon, f i nanc ial ratio, price, pharrnaceutical
70 Bttsiness attd I i t t trepreneurinl Reviev'
Sorne of lndof-anna's widely known products in
the dornestic market are OBH Corrbi PILrs. Indomaag.
and Prof lu.  The relat ively stable condit ion in social
politics appeared to have contributed greatly to the
increase of dornest ic investment in Indortesia. There
was an irrcrease of I 8.6% for foreign direct investnrent
and 30.3Y0 fbr domestic investtrent approvals in
January-September 2004 cornpared to the same
period in 2003. According to the data taken from
"Badan Koordinasi Penananran Moclal" (BKPM),
t h e  i n v e s t r n e n t  i n v e s t e d  i n  t h e  c h e m i c a i  a n d
pharmaceutical indLrstry sector were up to Rp 4,3
billions or28.2o/o fronr the total domestic investment
which put tlre chemical and pltarmaceutical industry
took the first rank in the dornestic and fbreign direct
investment along the year 2004.
The second place was taken by food industrl
fo ra to ta l  inves tmer r to f  Rp 3 ,7  b i l l i ons  or24 . lohof
the total domestic investment and I 3.3% or US$ 609. I
mi l l iorrs of the total  foreign direct investment.  ln the
year 2004, there were 198 manr,rfacturers in tlie
pharmaceutical indLrstry lvhich consists of 4 state-
owned companies. 3 I foreign direct investrnents, and
the rest were dotnestic players. Frotr the total of
198 manuf'acturers. 60of tlrerl domittates rnore than
80% of the total market share, while tlre rest 20%
was divided arnor.lg 140 manufacturers.
Based on the aforementioned condit ion. and
lookirrg at the good prospective of pharmaceutical
industry in Indonesia. it is not a surprise that a lot of
investors were willing to itrvest lteir money in this
sector. However, before deciding to invest in a stock,
investors must do the fundamental nalysis in order to
detennine the fair price of a stock. The price used to
be compared with the rnarket plice rvhether it is
undenralued and suitable to be acqr,rired oroverr',alued.
The irnportance of this assessuent whether techttical
or fundamental .  has drawn the attent ion to do a
research in analysis of firtancial petfornrance that aflect
stock prices in the pharrlaceutical indLrstry listed in
the Jakarta Stock Exchanse.
MBTHODS
Principal ly t l te marketable securi t ies can be
defined to have money valr-re. The value can be stated
by the market or rules or procedure of accottntartcy.
There are four concepts of valr"re tltat are cotnmoltly
knowt.t:
Going Concern Value, wltere the cotnpany's value
is related to its capability to generate future utcolre.
dividend distr ibut ion, and indef- ini te future growth;
Liquidation Value, where a company is valLred by its
assets after being sold and deducted: Market Value,
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which is the market percept ion of a conrpanv's bond
a n d  s t o c k :  B o o k  V a l u e ,  w h i c h  i s  b a s e d  o n  a
standardized accolrnt ing techniqr-re. The book value
is ident ical  with the par value or the nominal value.
This rat io is used to cor lpare stock pr ice according
to the market to the stock price based on the book
value.
The intr insic value of a securi ty is deterrnined
after weighing the factors inf luencing t l te valr .re.  In
other words. i t  is the real value o1'a rnarketable
securi ty that is di f ferent with the rnarket value. J 'he
f lnarrcial  rnanager is able to est inate the intr i rrs ic
value carefully by considering the f"r"rndarnental factors
that affect security value such as: Value ofthe Firm's
Assets; Likely Future Interest and Dividend: Likel i , '
Future Earnings: Likely Future Grou,th Rate. I t  is a
process of comparirrg the real value of a securi tv
w i th  the  nrarke t  ra l r re
The fundarnental factors that affect the value
usr-rally change slower than the nrarket. In a market
tlrat is ciraracterized as inrperf-ect, art analyst can hope
to local ize var iances between intr insic value and
rnarket dernand. J'he rnain ob.iective of intrinsic value
is to choose or separate cornparr ies ol stocks that
are overvalued and undervalued. l 'he intr insic value
analysis can not always be done accurately due to
three l i rni tat ions: Market place is slolv to recogrt ize
real value: Stocks of highly speculat ive f i rms: Fl igir-
gror.vth stocks. The second technique of sectrr i t l '
assessrnent that is of tert  used is the assessment by
considering the individLral stock prices cornpared with
other indicators in the market.  There are three tnain
factors in this approach: Depressed overall rnarket:
Industry corrparison and Cyclical ows. Capitalization
nrethod is a method to chauge firture iucome to be
present value or securi ty i r t t r i r ts ic value. Cornt lon
stock offers potential for firtLrre incotne gror'vtlt. and
this has to be revealed in an intr insic value analysis.
The investment rate of return basically is a retttrn
over a single period of t ime which is usLral ly a year.
+Rp
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Thc fbrnula can be writ ten as fcl l lorv
\ r l -  N0  +Cush l
E(rpn)l =
Where:
ts (tpn) - rate of retut-rr after period I e xpecteci
Nr - '  secur i t \ /  va lue at  t l ie  end of  per iod I
N, ,  -  beginning val r te on pornt  0
Cash,  -  a l l  recerved cash s ince point  0 t rnt i l  the end ot
Per iod l .
Zero Grorvth Dividends
PMT
PI" - -- atld ctl l1 6e rewriten as lbllorvs:
N  o  (Va lue  , , )= D/'.S I
Because DPS, : 
":;::ilJ 
lnn,ooni, stock in
per iod i  and ever l 'per iod in  the l i r tLr re rv i l l  be zero
grorvtlr or sirl i lar. ' lo cletertnirte the tlt i tt i tt l t l l l l  rate of
retunr. the rate of grorvtlt (g) ls detell l l irtcd as lbllou.
t.fs
t  =  y r , , ' ,  ( u " R L )
Irr order lbr the grou'1h to be O. tlrc percentage o1
retained eartting has to be 0. Therelbre. all l lPS ale
paid as DPS and t l te stock val t te is stated as:
N'  0 ( \ 'a lu. '  0)
D P S I  E P S I
KeQ'cq 1 Kc(rcq )
T'he third approach in the cotnnrorr stocli valttatiott
is by'considering the eant i t tgs and dividends gt 'ou in a
constant growtlt. Tlte tbrntLrla is as fbllou':
DT.S
E P S
,\ 'or l i , / , , . ' t ,  '=  -? l f  
'
r( r '( r irT t C
The Gordon llodt: I \\ as filst clevelclped b1' Gordorl
an expefi irr corpot'ate flnance. Sotltc considcratiolls
were put into tlte Inodel so that matltenlaticallv- it can
be used in deterrnining intr insic value of the stock.
There are three main lactors that are the focus of his
altentiort irr the tnodel design: Shareholder's Retr-trtl-
Single Variable. In Gordon's tnodel.  the shareholder 's
retum is ot l l ) , future dividend. not capital  gain.
The rnodel r'vas developed by cornparirtg the ltorntal
rate of return or the rli ltimal rate of returtr with actual
Div idend pa) 'out
or  can be rervr i t ten as fb l lou:
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rate o1'return. The rate of retttrrrs are divided into
rcqui led retLrrn (Ke).  actual return and i l tc lusi t l t l  o1'a
slon'th fhctor. 
' l-he 
efI'ect of variable glowth can be
seen in table 1 .
After comprehending t l te componelt ts in the
Gordon Model. tlren fbnnula can be nrodilled as follor,v:
Div  1
lntrin.sic tulue -
K"1'"q; - [K"r. ' .r , ]  [9'oREl
where:
Di t , l  :  Div idend in the tbrm of  cash in the current  year
( no\4')
hsl,rqr - Nonttal equity rate of return that the tnarket
walrts accordingl)' to the stock risk.
Kerr:qr : Actr-ral corporate equitl, '  rate o1-return (actual)
o/o RE -  Percentage of-  corporate EPS that  might  be
retained b1' the corPorate.
\ ra l id i t )  o1 'Cordor . t 's  rnodel  is  backed up in table
2.  The changc in d iv idend pa)out  . ' r ' i l l  a l l 'ect  the
oer l t lnrance or  a l te t '  thc in t r i l ts ic  va l l te :  houevel '  i t
depends on the re lat ionship bel ' ,veetr  actual  rate of
ret r r rn and nr in i l ra l  rate of  retur t t .
Basical ly ' the stock pr ice is  af fected by demand
and supply: horvever for a better stock price valttation.
ct)mparry"s operatiortal data suclt as aLrdited flnancial
reporl. corn pan)'s l irtLr e perfbrlttaltce atrd ecottollt ic
conci i t ior t  are reqLt i red.  I t t  general  there are tu 'c l
app roaches  i u  s tock  va lL ta t i t t t t :  t he  f t r nda lnen ta l
apploacl r .  l r 'h ich lbcuses on t l te  in t r i r rs ic  va lue.  which
is cornpanl"s l irtLrre capalri l i t l . by looking at its asset.
Table l. Growth Factor in Gordon Model
Reta ined
Earn ings
("1,)
\ 0
IPSiMl i t
Pr  Actual
Growth Explanat ion
0
0.05
0.05
0 .  r 0
0 .  l 0
U
0.050
0.50
0.60
No re ta inedN onr'
earn Ings
All protits ;rre
None d is t r ibuted as
div idend.
:  0.025
Grolvth
0.050 increase as
profit increase
Grolvth
lncrease as
0.060 reta ined
earn ings
higher.
Table 2. Intrinsic Value bv Cordon Model for different ROR and dividend
Minimal  Rate of  Return Capi ta l izat ion Rate Required
8 percent l0 percent l2 percent
if 3.ll -
8 % - ( 1 0 % x 7 0 % )
Itp 0.60 Rp 0.60
- - :  R p  2 0  :  R P  1 2i 0o  o  
d iv idend pa)  o r . l t
Rp 60
l 0 % - ( 1 0 % r 7 0 % ) 1 2 % - ( l j o k x 7 0 o / o )
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Thble 2. (continue) Intr insic Value by Gordon Model for dif ferent ROR and devidend
Minimal  Rate of  Return Capi ta l izat ion Rate Required
8 percent  l0  percent  12 percenl
50% devidend payout R p l R p l
--  :  Rp 20 - Rp 14.3
t0% - (10% x 50%) 12% - (10% x 50%)
R p l
- - :  R p  3 3 . 3
8 % - ( t 0 % x 5 0 % )
70% devidend payout Rp 0.60
- - :  Rp  6o
8%- (10%x30%)
Rp 0.60
-  - R p 2 0
1 0 % - ( 1 0 % x 3 0 % )
R p  1 . 4
:  R p  1 5 . 5 6
t 2 % - ( 1 0 % x 3 0 % )
I 00% devidend payout R p 2
- - :  R p  2 5
8 % - ( t 0 % x 0 % )
Rp 0.60 Rp 0.60
-  Rp 16 .67
t 2 % - ( t 0 % x 0 % )
Rp 60
t 0 % - ( 1 0 % x 0 % )
Example:All data was taken from a cornpany with EPS = Rp 2 ROE of l0%.
production, and marketing, and the teclrnical approach H2 : There is no significant eIlbct from retunr on equity
which focuses on clrafts wlrich is shoft time analysis,
used to predict he future price based ou tlte rrovetnent
of stock in the past. The needed inforrnation is trade
volume and capital  gain. Next in order to derivate
factors that can affect stock price, the Gordon Model
of div idend discoLrnted model is used (Jogiyanto
1998:76).
^ ROA r (l + Debr I Ecluirl ') x BV x (b)
r (Required Rate or J-ll#i. 
u.'"'.,,",.0 
by using
CAPM model r= rf+'?(rrn-rf)
therefore
Stock Price (Po) - f (ROA, ROE. b, BV DER, r)
Where:
ROA: Return on Asset  (7o)
ROE: Return on Equi ty  (%)
b = Payout  rat io  )  Div idend /  Earning per  Share
(:%)
BVS :  Book Value Equi ty  per  Share (%)
DER: Debt  to Equi ty  Rat io (%)
Stock Return (%)
Some hypothesis testing models that were used to see
factors that affbct stock price are in plrannaceutical
industry:
H 1 : There is no significant effect from retum on asset
to market stock price of firms
to market stock price of finns
: There is no significant eflbct frorn payout ratio to
market stock price of firms
: There is no significant effect fronr book value to
market stock price of finns
: There is no significant effect frorn debt to equity
ratio to market stock price of finns
H6 : There is no significant effect frorrr return on asset,
return on equity, payout ratio, book value per share
and debt to equity ratio altogether to market stock
price of finns.
This research was conducted to know t l re
intrinsic value condition and factors affecting stock
price thLrs their effect oward stock price. The research
des ig r r  was  qua l i ta t i ve  research  Lrs ing  da ta  and
concepts or theories ofvalue, valuation, approaches
to valuation. This research uses library research.
The quarrtitative data such as firm's financial data
were acquired from finls' publication to society clr
through JSX Capital Market reference centre. and
otlrer lass media. There are two steps in this research:
First analysingthe stocks using Gordon model to know
the stock's intrinsic value from each firm. second
comparing it with market stock price, and analysing it
using correlated research method or usiltg regressiorr
analysis to know which factors affect stock price and
how big the influence is. The variables in this research
are in table 3.
H3
H4
H5
Table 3. Variables and Measurements
Var iable Sutr Variable Measurement  Scale
Dependent Stock Price
Independent Return on Asset
Return on Equity
Pay out Ratio
a.  Net  Income
b. Total asset
a.  Net  Income
b. Total asset
a.  Div idend
b. Earning per Share
Individual stock price of pharmaceutical company
Ratio
Ratio
Ratio
Bttsiness antl  I :ntrepretteurial Review
This research used six research var iables: ROA,
ROE, Payout fatio (this ratio is Lrsed to know horv
rnuch portion of dividend fioni firnt's Itet incorne.
Payout rat io can be calculated by dividing dividend
with EPS), BVS (Book Vah-re per Share),  and DER
(Debt to Equity Ratio). The research popr,rlation was
pharrnaceut icalcompanies l isted on the JSX unt i l the
end of 2004. This research also used t l re. iudgrnental
sampl ing that is the non probabi I q, sampI ing techn ique.
Based on the techrr ique, the el igible sarnple is
phannacer,rtical industry companies listed on the JSX
unti l  Decernber 2004 and companies. that have
distribLrted dividends to their stockholders. Therefore
there were seven el igible companies.
Data analysis rnethod in this research rvas doue
by calcLrlating and using the Gordon model forrnr-rla to
know the stock's itttrinsic value artd other data analysis
method using conelation analysis ignificant con'elatiotr
frorn the two variables by using double regressiott
fonnula.
The correlation analysis was needed to know the
relatiorrship of independent artd depettdent variables.
The Lrsed analysis in this researclr  is the Pearson
correlatiorr. Tlte usage of determination coefficient
fonnula is to rneasure tlte contributiorr of independent
variables. The r-rsed regressiorr model in this researclt
was acquired by derivatiorr factors tlrat can affect stock
price by using Gordon approach of dividend discount
modelr,vith the eqr-ration f:
, , . .  _ 
Divit lanrl( D)
(r' 
.c )
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Therefore the regression model used in this research is:
Y = a + btxt+ b:x: + b.rx-; -t  b*t + b";x.;
Where:
Y- Stock price with proxy of phannaceutical company
indiv idual  s tock pr ice.
x, : ROA proxy of phanraceutical company ROA ratio
value.
4: ROE proxy of pharmaceutical company ROE ratio
value.
x, - Payout ratio of pharrnaceutical company individual
stock return value.
x. :  Book value per  share proxy of  pharmaceut ica l
corxpany BVS ratio value.
x. - DE,R proxy of pharmaceutical company DER value.
a - conslanl
b -  Regression Coel f ic ient .
RESULT AND DISCUSSION
Retu rn  on  asse t  (ROA) .  H igh  ROA g i ves  a
perspective that a cornpany can effectively runs its asset
to get high profit and low ROA gives a perspectivethat
a conrpany cannot effectively runs its asset to get high
profit. Based orr table 4, it can be seen that ROA frorn
the seven companies in the phannaceutical indLrstry
fluctr-rated every year. The highest average ROA for
tlre year 2001-2004 was gained by PT Merck Tbk
20.40%. and the lowest was gained by PT Indofarma
Tbk 3.8%.High ROE gives a perspective that a company
can effectively runs its eqLrity to get high profit arrd low
ROE gives a perspect ive that  a company cannot
eflectively runs its eqLritv to get high profit.
Bydoingsubst i t t t t iot t theabovernodel.detai lof  Based o1 table 5. i t  can be seen that ROE from
the equat iort  catt  be: Stock Price (Po) :  f  (ROA, the seven contpauies ip the pharmaceut ical  indgstry
ROE, b, BV. DER. r) fluctLrated every year.
Table { .  Return on Asset
Year Average
2001-2004Pharmaceut ica l  Company 2003 2001
PT Dankos Laboratories Tbk
PT Indof'arma Tbk
P'I Kalbe Farma Tbk
PT Kirnia Farma Tbk
PT Merck Tbk
PT Br is to l  Myers Squibb Indonesia - fbk
PT Tempo Scan Pacific Tbir
1 5 . 7 5
0.06
1 0 . 9 1
4.68
1 9 . 8  i
14.29
1 2 . 9 1
1 2 . 5 6
-5 .78
l l . 7 r
4 .06
t 7 . 1 2
1 1 . 5 2
r 3 . 8 1
I  t . 6 2
9 . l  r
1 0 . 7 1
2.66
t 6 . 6 1
7 . 1
I  5 .02
1 0 . 1 7
n . 9 4
5 . 5 4
1 0
27.39
-  t  - ) . . )J
1 9 . 0 5
t2 .525
3.832-5
9 .1  t75
5 . 3 5
20.3915
4.895
| 5.2t25
Table 5. Return on Equity
Average
200I-200,$Pharmaceut ica l  Com pany 2003 200r
Year
PT Dankos Laboratories Tbk
PT Indofarma Tbk
PT Kalbe Farrna Tbk
P' I  K imia Farrna ' l  bk
29.8  r
0 .  l 5
28 .87
6.7  |
26 .8
- l  1 . 4 3
36.42
6.07
30.57
1 6 . 5 1
5 l . l  I
4 .04
1 1  1 A
t 8 . 7 9
3 5.4c)
1 4 . 3  I
t2 .525
3 . 8 3 2 i
9 . 7 1 1 5
5 . 3 5
7,1 l lus ine ss a nrl  I ' ,n tre pre tte u r i  tr  I  l let i  etr \ o l i | 1 i
Table 5. (continue) Return on Equitv
Yea r
2002 200 I
Average
200r-2004Pharrnaceut ica I  Corn pany 200,1 2003
PT Merck Tbk
PT Br is to l  Myers Squibb Indonesia ' l -bk
PT Tempo Scan Pacific Tbl<
24.7 |
2 3 . 5 3
12.91
2 i .03
18 .8  r
1 3 . 8 1
19 . - s9
1 i . 7 5
r  5 .01
j .1.96
3 i . e 6
1 9 . 0 5
20. i975
4.895
l - 5 . 2 1 2 5
The highest avera-se ROE for the 1'ear 2001-
2004 rvas gained by PT Kalbe FarrnaTbk 31.97%.
and the lorvest \\'as sainecJ b1' P'f Indofarrra Tbk
6.01%.The s tna l le r  the  pa lou t  la t io  g le t : .  the  less
in te res t ing  the  cor r rpanv 's  s tock  rv i l l  be .  Occurs
because investor vi l l  see that the companv is less
interest ing because i t cannot give the high return on
investrnent.  The higher this rat io gets.  the rnore
interest ing the companv's tock w i l l  be. This occurs
because investor rvi l l  see that the colnpany rvi l l  g ive
high retr-rrn orr i r rvestnrerrt .  Hor.vever i t should be
accompan ied by' goocl colnpany performance.
Based on table 6. i t  carr be seen that payout rat io
f iorn the seven compauies in the pharrnaceLrt ical
industry f-luctuated every year. 1-he highest average
payout fbr the ;"ear 2001-2004 rvas gained by P'I
Merck Tbk 4l 1 .278%^ and the lowest rvas gained b.'-
PT Kalbe Farrna -fbk l%. as BV per share gets
higlrer.  the demand gets high as lvel l .  BVS depicts
h istor ical  estabI is i rrrent cost and cornpauv's physicaI
asset. A compauy that has a good perfbrrrance r.vill
be able to 
-{ain lelat ivel , '  h igh earnings because of
the competi t ive prodLrct ost so that i t  tends to have
hisher narket value or at least s imi lar v i th i ts physical
asset book value.
Based ou table 7" i t  can be seen t l rat  book value
p e r  s h a r e s  f ' r o r l  t h e  s e v e n  c o l n p a n i e s  i n  t h e
phannaceLrt ical  inclustrv f luctuated every year.  The
h ighest averase pa)'or-rt fbr the 1,ear 200 l-2004 rvas
obtained by PT Tempo Scan Pasi l lc lbk 3215.5. and
the lorvest rvas obtained by PT Bristol M;-ers SqLribb
' f  bk  6 .25 .
The smal ler DER rat io gets,  the better i t  rv i l l  be
because investor rvi  I  I  perceive that the r isk of 1ai  Iure
in f i r l f i l l ing cornpanv's l iabi l i ty rv i l l  be snral ler becaLrse
it  is backed up by i ts equitv.  High DER rat io rneans
investorrvi l l  perceive thatthe r isk of fbi lLrre in f i r l f i l l ing
compan) 's  l iab i l i t y  rv i l l  be  h igher .  Th is  rv i l l  rnake
i,rvestor to be careful  rv i th companies uch as these.
Based on table B, it can be seen that de bt to eqLrit)
ratio fiorn the seven cornparries in the phannaceutical
industry f'luctr-rated verv vear.
Thble 6. Pavout Ratio
Year Average
2001-200. tPharmaceut ica l  Cornpany 2004 2003 2002 2001
PT Dankos Laboratories Tbk
PT Indotarrna ' fbk
PT Kalbe Farma J"bk
PT Kirn ia Farrra ' fbk
PT Merck Tbk
PT Br is to l  Myers Squibb Indonesia Tbk
PT Tenrpo Scan Paciflc lbk
0 . 1  I
0
0 .0  r
0 . 3 2
146.61
956.34
0.67
0. i  7
U
0.03
0.23
589.47
7 8 . 1  5
0 .69
0.44
0.7-5
0
2.2
i08 .97
0
0.5  t
0 .32
0.68
0
0
0
0
0.5'7
0 .3  i
0 .3  575
0 . 0 1
0.6875
1 t  | . 2 1 1 5
258.6225
c . 6 l
Table 7.  Book Value per  Shares
2004 2003 2002 200 r
Average
200r-2004
YearPha  rmaceu t i ca l  Com pany
PT Dankos Laboratories Tbk
PT Indofarrna Tbk
PT Kalbe Farma Tbk
PT Kimia F'arrna Tbk
PT Merck Tbk
PT Br is to l  Mvers Squibb Indonesia ' fbk
PT Terrpo Scan Pacific Tbk
302
84
285
142
8
t 2
3.681
203
l 1 3
1 8 9
r 3 6
7
l 0
3 .309
148
n4
l l t
t20
1
8
3.042
222
r 5 5
t2
t 2 l
5
2.824
2 1 8 . 7 - 5
l3  I  . -5
164.25
t3 t .25
6.15
6.25
3 2  r 5 . 5
?able 8. Debt to Equity Ratio
PT Dankos Laboratories l 'bk 0 E 8 i  1 2
Year
j . 6 l
2001
i . \ 2 . 7 5
Average
2001-2004i]harmaceutical Companv 2002?tla4 2003
lJ l r , r lng.rs u nd Ln t  re p rc t ta ur  i  t r  I  I lev i  ev
Pharmaceut ica l  Company
Table 8. (continue) Debt to Equity Ratio
Yea r
AVIAiT-DY 1 5
20032001 2002 2001
Average
2001-200,1
PT Indofarma Tbk
PT Kalbe F-anra Tbk
PT I(irnia Falnra -l 'bk
PT Merck Tbk
PT Br is to l  M1'ers Squibb Indonesia Tbk
PT Tenrpo Scan Paciflc Tbk
1. .16
t . . 14
0. .11
0.1-s
0.6-5
0 .2
0.96
1 . 8 4
0..19
0.22
0.64
0.2
0 .8
1 . 4  r
0 . 5 2
0 .  I 8
0 .94
0.24
0 . 5 6
4.91
0.13
0.28
0 . 3  I
0.945
2 . 9 1 5
0.4615
0.2325
-0 .33
0.2315
The highest avcra-se clcbt o equit)  rat io fbr the
l v e a r  2 0 0 1 -  1 0 0 . 1  v n a s  o b t a i n e d  b v  P T  D a n k o s
L.aborator ies Tbk 312.15" -  and the iou,est rvas
obtained by PT. Bristol  M1,ers SqLribb' fbk - i i%. The
main  ob jec t ive  o f  in t r ius ic  va lue  ana lvs is  i s  to  se lec t
or separate fintts thus separate the tx'ervalued and
rundervalued stocks.
Basecl on table f .  i t  can be seen that stock pl ice i rr
the market lbr corrpanics rn the phannaceLrt ical
industry is overvaiued. l -he rnarket pr ice tbr P-f
Darrkos Laborator ies Tbk n'as Rp 600 rvhi le the
intr insic \alLle was Rp 76.58 rvhich is overvalLred. ' l -he
inost overvalued stclck price belon-us to PT Merck Tbk
rvi th market value of Rp 20300 ancl iutr iusic value of
Rp 8945.97 whiclr  is ovelvaluecj.
'Ihe least overvalued stock price belongs to PT
Indofalma ' l 'bk with urarket value of Rp 170 and
intr insic valLre of Rp l6t l .45 r 'vhich is overvalued.
The Pearson correlat ion shows that the ROA as
inclepenclent variable has strong correlation (0.604) rvith
r larket pl ice as deperrdent var iable. ROE variable has
u eak correltrtion (0. 1 96) to nrarket price as clepe ndent
va l iab le .  pa \ 'ou t  ra t io  var iab le  has  vcry  s t rong
correlat iorr  \0.917) rvi th nrarket pr ice as dependent
variable. book value per sharc varrable has very lveak
corrclat ion and reverse (-0.138) to nrarket pr ice as
dependent variable rvhich lreans that cverJ l% book
value per share rvi l l  
_9ive a decrease of 138%. debt to
ec;Lrity ratio variable has firir correlation (0.'156) to
narket pr ice as deperrdent var iable. ( table l0)
Table 9. Stocli Price Comparison
Pharmaceut ica l  Conr panl ' Market  Value In t r i ns i c  Va lue lnformat ion
PT Dankos l .aborator ies ' fbk
PT Indofarrna I 'bk
PT Kalbe irarma Tbk
PT Kinria Farma lbk
PT Merck Tbk
PT Br is to l  Myers Squibb Indonesia ' fbk
PT'tr 'empo Scan Pacific -fbk
600
t70
- l l -5
l6 -s
20300
I 0500
5900
76 .5  8
I  68.4-5
8 . 7 9
r 0 0 . 8 8
8945 .97
4 3 1 6 . 1 9
I  5,10.65
Overvalued
Overvalued
Overvalued
Overvalued
Overvalued
Overvalued
Overvalued
Table |  0 .  Corre lat ions analys is  of  lactors af fect ing stock pr ice
Stock Pr ice ROA ROE PAYOUT BVS D E R
Pearson
Correlation
Stock Pr ice
R.OA
ROE
PAYOU-f
B V S
DER
1 . 0 0 0
.604
.  1 9 6
.917
- . r 3 8
-.456
604
1 . 0 0
0
50-5
4-58
306
. 1 2 2
.  1 9 6
._50.5
1 . 0 0 0
. t97
- .050
. 5 5  |
.971
.rl5 8
.197
1 . 0 0 0
- .305
- . 4 1 )
- . 1 3 8
.306
-.050
- .305
1 . 0 0 0
-.245
- .456
r ')')
. 55  r
- .425
-.245
1.000
Sig .  (  l - t a i l ed ) Stock Price
iroA
iL0E
PAYOUT
iJVS
, -  i r K
.076
.331
.000
. r84
. i ) /
.016
. t24
. l 5 l
. l ) '
.391
.331
|  1 /
- t : q
. 3 3 6
.45  8
.  r 0 0
.000
. l 5 l
.336
. l )  r
. t 7  |
. i84
.252
.458
. l )  )
.298
. t 5 2
,397
.  1 0 0
. t 7  |
.298
Slcci i  i ] : ' ice
(.(; ,", a
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Table 10. Correlations analysis of factors affecting stock price.
Stock Price ROA ROE PAYOUT BVS D E R
1
1
l
l
1
1
1
1
7 1 1 1
l 7 7 l
1 1 1 7
7 7 7 7
ROE
PAYOUT
BVS
DER
N
Table l l .  ModelSummary (b)
Model R Square Adjusted R Square S td .E r ro r  o f  t he  Es t ima te  Du rb in -Wa lson
1.000 (a) 1.000 998 I  3 t . 1 2 7 8 4 t . 1 4 2
a. Predictors:(Constant), DER. ROA, BVS. ROE, PAYOUT
b. Dependent Variable: Market stock price
Thble I2.ANOVA(b)
Sum o fSqua res d f Mean Square Sig
Regression
Residual
Total
68236864
t]  451 . l65
68254322
t3641312.190
11 457 . l65
181.131 .027(a)5
I
o
a. Predictors:(Constant), DER, ROA, BVS, ROE, PAYOUT
b. Dependent Variable: Market stock price
Table | 3. Coefficients (a)
Model
Unstandard ized
Coefficients
Standardized
Coefficie nts Sie.
Std.Error Beta
(Constant)
ROA
ROE
PAYOUT
BVS
DER
- 3 0 2 . 2 . 1 1
1 0 5 . 8 3 3
-46.181
2 0 . 0 1 - 5
. J o +
340.162
t22.290
1 3 . 5 7 8
8 . 8 1 0
. 6 t 3
.011
9c).349
.  1 9 8
- . 1 5 8
r . 0 0 3
. t 2 1
. 1 2
-2 .411
1 .194
- 5 . 3  r 0
32.642
5 . t 4 2
J . + J U
)  t {
. 08  r
. l  l 9
. 0 1 9
. t 2 2
. t 8 t
a. Dependant Variable: Market stock price
Frorn table I l. it can be seen that 100% rrarket
pr ice as dependent var iable can be explained by
variatioll of ROA, ROE, payoLrt atio, book value per
share and debt to equity ratio.
From the result of ANOVA test on table 12. F is
181.737 with the signi f icant level of  0.021, which
lreans that regression model calt be used to predict
the dependent variable ofnrarket stock price or it cau
be said that the indepertdent variables of ROA, ROE.
payout ratio, book value per share, and debt to equit,r'
ratio affect rnarket stock price.
The regression linear test provides result: Cortstattt
-302.217 wliich mearts that if all indeperrdettt variables
are zero. then market stock pr ice is -302.217t ROA
coefficient of 10,5.833 states that evety 196 ittclease
will add stock price of 105.833 with the ceteris paribus
assumptiou of ; ROE, coefilcient of -46.78 i states that
every lo% decrease will clecrease tlte stock price of
46.181 with the ceter is par i t rus assunrpt ion; Payout
rat io coeff ic ierr t  of  20.0 !  5 siates that ever1, l%o
ir.rcrease wi l l  increase t i re stock pr ice of 20.015 rvi th
the ceteris paribus assumption of; Book value per share
coefficient of 0.364 states that every 1o% increase will
increase the stock price of 0.364 with the assumption
of ceteris paribus. Debt to equity ratio coefficient of
340.162 states that every loh increase will increase the
s tock  pr ice  o f  340.762 w i th  the  ce ter is  par ibus
assumption of.
CONCLUSION
This research was conducted to analyze the
influence of several factors affecting stock price of
firms irr the pharmaceutical iudLrstry that are listed in
the JSX by Lrsing l' inarrciai ratios and based on tlte
Gordon modei approach. From the data and the
ana l ls is .  i t  was  be  conc luded tha t  ROA,  ROE.
book valLre per share. anci debt to equity has a very'
weak inf luence to stock pr ice.
Only pavout ratio had the significartt iuf'luence to
stock price of iinrs in the pharrnacer-rtical industry
i i s ted  on  the  iSX.
Busi ne ss ancl Entrepre nettr iu I  Rev iev,
It was also conclLlded the hypotheses that: There
is no sigrrificant effect frotl return on asset o market
stock price of firms irr phannaceutical industry. There
is no significant effect fi'orn return on equity to market
price of firrns in pharmaceLrtical indLrstry. Thele is uo
significant effect frorn payout ratio to market stock
price of firms in pharrnaceutical industry. There is no
significant effect from book value to market stock price
of f i r rns in pharrnaceLrt ical  industry.  There is no
significant effect from debt to equity ratio to market
stock price of firms in phannaceutical indLrstry. There
is significant effect from return on asset, retum ou
eqLrity, payoLrt atio, book value per share and debt to
equity ratio altogether to market stock price of firms
in phannaceutical industry.
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